期刊文献+

三维全息原子场作用矢量用于HEPT类抗艾滋病药物的QSAR研究 被引量:11

QSAR Studies of Anti-HIV Drug HEPT Using 3D-HoVAIF
下载PDF
导出
摘要 采用本实验室新近提出的三维全息原子场作用矢量表征34个1-[(2-羟乙氧)甲基]-6-苯硫基胸腺嘧啶(HEPT)类抗艾滋病药物结构并与其活性建立定量构效关系模型.采用逐步回归对变量进行筛选后,运用多元线性回归(multiplelinearregression,MLR)建模的复相关系数(Rcu2m)、交互校验的复相关系数(Qcu2m)和模型的标准偏差(SD)分别为Rcu2m=0.928、Qcu2m=0.883与SD=0.43,均优于Hancsh报道的值(Rcu2m=0.911、Qcu2m=0.863与SD=0.45).模型具有良好的稳定性和预测能力,表明三维全息原子场作用矢量能较好表征该类分子结构信息,值得进一步推广应用. A newly developed three-dimensional holographic vector of atomic interaction field (3D-HoVAIF) was used to describe the chemical structure of anti-HIV drug-34 1-[(2-hydroxyethoxy)-methyl]-6-(phenylthio) thymine (HEPT). After the structural characterization, the descriptors obtained were screened by stepwise multiple regression (SMR). The cumulative multiple correlation coefficient(Rcum^2), cumulative leave-one-out cross-validated(Qcum^2, and standard error (SD) were Rcum^2=-0.928, Qcum^2=0.883, and SD= 0.43, respectively, which were all better than previous report (Rcum^2=0.911, Qcum^2=0.863, and SD= 0.45). The result showed that the model had favorable stability and good prediction capability and the 3D-HoVAIF was applicable to the molecular structural characterization and biological activity prediction.
出处 《物理化学学报》 SCIE CAS CSCD 北大核心 2006年第6期721-725,共5页 Acta Physico-Chimica Sinica
基金 山西省工业攻关基金(2006031204) 重庆市应用基础(01-3-6)资助项目
关键词 三维全息原子场作用矢量 1-[(2-羟乙氧基)甲基]-6-(苯巯基)胸腺嘧啶 定量构效关系 抗艾滋病药物 Three-dimensional holographic vector of atomic interaction field (3D-HoVAIF), 1-[(2-hydroxyethoxy)- methyl]-6-(phenylthio)thymine (HEPT), Quantitative structure-activity relationship (QSAR), Anti- HIV drug
  • 相关文献

参考文献17

二级参考文献29

  • 1李英富.非核苷类HIV-1反转录酶抑制剂:一类新的抗艾滋病药物[J].国外医学(药学分册),1994,21(4):207-213. 被引量:2
  • 2关崇芬,吴小闲,卢耀增.中研Ⅰ号方治疗猴艾滋病模型的实验研究[J].中国中医药信息杂志,1995,2(5):42-42. 被引量:21
  • 3杨秀芝,魏月芳.抗艾滋病药物的研究动态[J].天津药学,1995,7(1):57-58. 被引量:3
  • 4德功.全球艾滋病患者达4000万人[N].中国医药报,2002.7.16.
  • 5徐铮奎.第三代艾滋病药物初露端倪[J].医药经济信息,2001,6:25-25.
  • 6Pharmaprojects, accession No. 16581.2002,11.
  • 7Manette T, Jmes B,Mark H, et al. Zidovudine treatment in patients with primary (acute) human immunodeficiency virus type 1 injection :A randomized,double-blind,placebo-controlled trial. J Infect Dis,1998,178:80.
  • 8Gadi B,Dominique A,Marka W, et al. The thicarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of (AZT)againt AZT-resistant human immunodeficiency virus type 1. Antimicrob Agent Chemother, 1999,43(2) :259.
  • 9Mairtin M ,Marcus C,Arlene H, et al. A preliminary evaluatinn of nelfinavir melfinavir mesylate,an inhibitor of human immunodeficiency virus(HIV)-1 protease to treat HIV infection. J Infer Dis,1998,177:1533.
  • 10Amilcar T ,Anac P,Koko O, et al. Getic variation and susceptibilities to protease inihibitors among subtype B and F isolates in brazil. Antimicrob Agent Chemother, 1999,43 (2): 253.

共引文献111

同被引文献108

引证文献11

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部